Improving the specificity of digoxin immunoassays
1Department of Pathology, University of Louisville, School of Medicine, KY.
Wiener Klinische Wochenschrift. Supplementum
|January 11, 1992
Summary
Immunoassays have improved digoxin measurement, but endogenous digoxin-like immunoreactive factors (DLIF) still challenge accuracy. Characterizing DLIF is key to developing more specific digoxin assays.
Area of Science:
- Clinical Chemistry
- Immunology
- Biochemistry
Background:
- Immunoassays have enhanced digoxin serum measurement reliability.
- Measuring digoxin is challenging due to low concentrations, narrow therapeutic ranges, and endogenous digoxin-like immunoreactive factors (DLIF).
Purpose of the Study:
- To describe recent developments in characterizing DLIF from bovine adrenal cortex and human serum.
- To review techniques for reducing DLIF cross-reactivity in digoxin immunoassays.
Main Methods:
- Characterization of DLIF from bovine adrenal cortex and human serum.
- Review of techniques to reduce DLIF cross-reactivity.
Main Results:
- A principal endogenous molecular factor (DLIF) in humans cross-reacts with anti-digoxin antibodies.
- DLIF can be present at concentrations high enough to interfere with most digoxin immunoassays.
- Isolation and purification of DLIF offer new strategies for selecting specific anti-digoxin antibodies.
Conclusions:
- DLIF poses a significant challenge to accurate digoxin immunoassay measurements.
- All digoxin immunoassays require testing for interference from endogenous DLIF.
- DLIF characterization and purification enable the development of more accurate digoxin immunoassays.
More Related Videos
09:08Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens
Published on: September 12, 2016
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
Related Concept Videos
01:33Enzyme-Linked Immunosorbent Assay
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...